Company Description
Seaport Therapeutics is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders.
Through our differentiated approach, we identify clinically validated mechanisms with established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects.
We apply our proprietary GlyphTM platform to overcome those limitations and invent innovative oral therapies.
Glyph is a lymphatic-targeting prodrug technology which is designed to bypass first-pass metabolism and thereby enhance a drug’s oral bioavailability and reduce side effects.
This process, which we call “Glyphing,” also creates new composition of matter intellectual property.
We aim to develop novel, leading treatment options that will make a significant impact for patients and their families.
| Country | United States |
| Founded | 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Daphne Zohar |
Contact Details
Address: 101 Seaport Blvd., Floor 12 Boston, MA 02210 United States | |
| Phone | (617) 807-4062 |
| Website | seaporttx.com |
Stock Details
| Ticker Symbol | SPTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2042347 |
| Employer ID | 99-2235719 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daphne Zohar | Chief Executive Officer and Director |
| Michael C. Chen, Ph.D. | Chief Scientific Officer |
| Lana Gladstein, J.D. | General Counsel |
| Antony Loebel, M.D. | Chief Medical Officer |
| Lauren A. White | Chief Financial Officer |
| Steven M. Paul, M.D. | Director and Board Chair |
| Eric Elenko, Ph.D. | Director |
| James I. Healy, M.D., Ph.D. | Director |
| Robert J. Hombach | Director |
| Robert Nelsen | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 27, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jan 29, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Nov 21, 2025 | DRS | [Cover] Draft Registration Statement |
| Oct 31, 2024 | D | Notice of Exempt Offering of Securities |